CMS Developing Guidance On Coverage Decisions For Clinical Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
The guidance will address questions about CMS’ priority setting and methodologies for making coverage decisions in the future. The document will be one of the first produced under CMS’ new guidance development process, details of which will be released in the next two weeks.
You may also be interested in...
CMS Colorectal Cancer Drug Policy Will Not Limit Current Off-Label Coverage
The Centers for Medicare & Medicaid Services releases its final national coverage determination for Avastin, Erbitux, Eloxatin and Camptosar. The final determination is in line with the draft NCD, covering off-label indications that are included in certain major compendia and are part of nine National Cancer Institute clinical trials.
CMS Colorectal Cancer Drug Policy Will Not Limit Current Off-Label Coverage
The Centers for Medicare & Medicaid Services releases its final national coverage determination for Avastin, Erbitux, Eloxatin and Camptosar. The final determination is in line with the draft NCD, covering off-label indications that are included in certain major compendia and are part of nine National Cancer Institute clinical trials.
CMS To Fund Clinical Trials Evaluating Off-Label Use Of Avastin, Erbitux
Under the agency’s proposed national coverage decision for colorectal therapies, CMS will fund costs of experimental drugs and routine care in nine National Cancer Institute trials. Use of Avastin in patients with colorectal cancer in the adjuvant setting and use of Erbitux in head and neck cancers are among the indications being studied in the NCI trials.